News

AVANT BIO Announces Investments in Nomic Bio, PathPresenter, and PL BioScience

We’re excited to announce our recent participation in a series of key financing rounds, reinforcing our mission to support visionary companies developing today’s cutting-edge solutions for HealthTech, Life Sciences research, and drug development.

Press Release

AVANT BIO invested in Nomic Bio’s latest Series B financing, an oversubscribed round that brings the company’s total funding to $60 million. Nomic Bio, known for its groundbreaking nELISA platform’s high-throughput capability, is positioned at the forefront of protein profiling services.

Visit Nomic Bio to learn more.

PathPresenter’s $7.5 million Series A funding round was led by AVANT BIO.  The round is expected to propel the adoption of PathPresenter’s vendor-agnostic pathology workflow solution to enhance preventative care and improve patient outcomes, with over 50,000 users worldwide.

Visit PathPresenter to learn more.

AVANT BIO also joined PL BioScience’s €7.8 million Series A financing round to help accelerate the commercialization of their sustainable, non-animal-derived cell culture media business.

Visit PL BioScience to learn more.

We thank our Limited Partners for their tremendous support and their confidence in our team and AVANT BIO’s mandate.